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Introduction
Tumor necrosis factor receptor-associated periodic syn-
drome (TRAPS) is an autoinflammatory disease inher-
ited in an autosomal dominant fashion. TRAPS develops
secondary to mutations in TNFRSF1A. Associated symp-
toms include periodic attacks of peritonitis, constipation,
arthritis in large joints, arthralgia, migratory rash with
underlying myalgia, periorbital edema, conjunctivitis,
splenomegaly, and increased risk for AA amyloidosis.
Typically, attacks last from days to weeks. The common
treatment modalities are corticosteroids, the p75 TNFR:
Fc fusion protein, etanercept, and IL-1 antagonists.
Recent studies suggest that multiple cytokines are
involved in the pathogenesis of TRAPS. To date, there
are limited data comparing the efficacy of etanercept
and IL-1 inhibitors in TRAPS.
Objectives
To explore the efficacy of anakinra in nine TRAPS
patients who had modest response while on etanercept.
Methods
CRP and ESR were measured serially in nine patients
with TRAPS (eight adults and one child) who had been
initially treated with etanercept and were subsequently
switched to anakinra. Patient records were evaluated for
clinical and laboratory associations. Patients with the
R92Q and P46L variants were excluded from our analysis.
Results
Eight adult patients and one child with TRAPS were
switched from etanercept to anakinra treatment due to
poor symptom control and persistent elevation in
inflammatory markers. Among all nine patients, the
range of ESR before starting anakinra (no patients were
actively flaring at the time labs were drawn) was 37-91
mm/hr and after was 5-18 mm/hr. The range of CRP
before starting anakinra was 18.10-186 mg/L and after
was <0.5-8.85 mg/L. The etanercept doses ranged from
50 mg weekly to 75 mg weekly. The anakinra doses ran-
ged from 100 mg daily to 300 mg daily. One patient
with AA amyloidosis had normalization of proteinuria
and stabilization of creatinine within 16 months of start-
ing anakinra. Patients reported fewer flares, shorter
duration of flares, and decreased necessity for additional
medications during flares (corticosteroids and narcotics).
Conclusion
Our findings indicate that in some patients, anakinra is
superior to etanercept for the treatment of TRAPS. Of
the nine patients, all of them experienced clinically sig-
nificant decreases in inflammatory markers including
CRP and ESR as well as clinical improvement in symp-
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